Funding Partnerships Leverage ongoing funding momentum with cystic fibrosis foundations and European public funds to accelerate CRISPR and phage-based antimicrobial programs, creating grant-backed or co-development opportunities for SNIPR Biome.

Diversified Pipeline SNIPR Biome's pipeline spans CRISPR medicines and phage-enabled approaches for antimicrobial resistance, enabling licensing or joint development deals with pharma partners seeking platform capabilities.

CF Pseudomonas Focus Targeting Pseudomonas infections in cystic fibrosis patients opens doors to hospital and clinic partnerships, payer discussions, and potential phage-CRISPR combination therapies with patient-focused organizations.

European Gateway Based in Denmark with active European funding access, SNIPR Biome is well positioned for EU collaborations, CRO/CMO partnerships, and scalable manufacturing partnerships within the EU.

Lean Partnership As a lean growth stage company, SNIPR Biome presents opportunities for early-stage licensing, data-sharing collaborations, and outsourced development and manufacturing arrangements to accelerate timelines.